Correlation of Thromboelastography with Apparent Rivaroxaban Concentration: Has Point-of-Care Testing Improved?. (February 2020)

• Record Type: Journal Article
• Authors: Myers, Sara P.; Dyer, Mitchell R.; Hassoune, Adnan; Brown, Joshua B.; Sperry, Jason L.; Meyer, Michael P.; Rosengart, Matthew R.; Neal, Matthew D.
• Is Part Of: Anesthesiology. Volume 132:Number 2(2020)
• Publication Date: 2020-02
• Subjects: Anesthesiology -- Periodicals; Anesthetics -- Periodicals; Anesthesia -- Periodicals; 617.9605
• DOI: 10.1097/ALN.0000000000003061
• Languages: English
• ISSNs: 0003-3022

Abstract

Abstract : Background: Concern remains over reliable point-of-care testing to guide reversal of rivaroxaban, a commonly used factor Xa inhibitor, in high-acuity settings. Thromboelastography (TEG), a point-of-care viscoelastic assay, may have the ability to detect the anticoagulant effect of rivaroxaban. The authors ascertained the association of apparent rivaroxaban concentration with thromboelastography reaction time, i.e., time elapsed from blood sample placement in analyzer until beginning of clot formation, as measured using TEG and TEG6S instruments (Haemonetics Corporation, USA), hypothesizing that reaction time would correlate to degree of functional factor Xa impairment. Methods: The authors prospectively performed a diagnostic accuracy study comparing coagulation assays to apparent ( i.e., indirectly assessed) rivaroxaban concentration in trauma patients with and without preinjury rivaroxaban presenting to a single center between April 2016 and July 2018. Blood samples at admission and after reversal or 24 h postadmission underwent TEG, TEG6S, thrombin generation assay, anti–factor Xa chromogenic assay, prothrombin time (PT), and ecarin chromogenic assay testing. The authors determined correlation of kaolin TEG, TEG6S, and prothrombin time to apparent rivaroxaban concentration. Receiver operating characteristic curve compared capacity to distinguish therapeutic rivaroxaban concentration ( i.e ., greater than or equal to 50 ng/ml) from nontherapeutic concentrations. Results: Eighty rivaroxaban patients were compared to 20 controls. Significant strong correlations existed between rivaroxaban concentration and TEG reaction time ( ρ = 0.67; P < 0.001), TEG6S reaction time ( ρ = 0.68; P < 0.001), and prothrombin time ( ρ = 0.73; P < 0.001), however reaction time remained within the defined normal range for the assay. Rivaroxaban concentration demonstrated strong but not significant association with coagulation assays postreversal (n = 9; TEG reaction time ρ = 0.62; P = 0.101; TEG6S reaction time ρ = 0.57; P = 0.112) and small nonsignificant association for controls (TEG reaction time: ρ = −0.04; P = 0.845; TEG6S reaction time: ρ = −0.09; P = 0.667; PT-neoplastine: ρ = 0.19; P = 0.301). Rivaroxaban concentration (area under the curve, 0.91) and TEG6S reaction time (area under the curve, 0.84) best predicted therapeutic rivaroxaban concentration and exhibited similar receiver operating characteristic curves ( P = 0.180). Conclusions: Although TEG6S demonstrates significant strong correlation with rivaroxaban concentration, values within normal range limit clinical utility rendering rivaroxaban concentration the gold standard in measuring anticoagulant effect. Abstract : The use of a modified thromboelastography assay demonstrated significant correlations with rivaroxaban concentrations but values were within normal ranges, and therefore clinical utility is limited. As a result, other methods to assay rivaroxaban and other Xa inhibitor concentrations are needed to determine the anticoagulant effects of these agents when needed.Supplemental Digital Content is available in the text.